Evidence map›Paper›PMID 33893957›Full record

ArticleBulletin of experimental biology and medicine2021

Choice of Tactics for Experimental Therapy of Chronic Heart Failure with ALM-802 Compound.

V V Barchukov, I B Tsorin, M B Vititnova, A O Efimova, A M Likhosherstov, G V Mokrov, S A Kryzhanovskii

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Study of the NBulletin of experimental biology and medicine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

V V BarchukovV. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.
I B TsorinV. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.
M B VititnovaV. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.
A O EfimovaV. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.
A M LikhosherstovV. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.
G V MokrovV. V. Zakusov Research Institute of Pharmacology, Moscow, Russia.
S A KryzhanovskiiV. V. Zakusov Research Institute of Pharmacology, Moscow, Russia. SAK-538@yandex.ru.
Institute of Pharmacology Russian Academy of Medical Sciences · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cardioprotective activity of ALM-802 compound was demonstrated in model experiments simulating postinfarction chronic heart failure in rats forming in 90 days after anterior transmural myocardial infarction. ALM-802 decreased the left ventricle and improved its inotropic function (p=0.038). This effect was observed in case of systematic administration of ALM-802 over 28 days (starting from day 91 after infarction modeling). This is apparently the minimum time for the cardioprotective effect of ALM-802 to prevent or treat the resulting heart failure, because short-term systematic therapy (15 days) produced no positive effect.

Indexed as

AnimalsChronic DiseaseDisease Models, AnimalHeart FailureHeart VentriclesMaleMyocardial InfarctionRatsALM-802 compoundanterior transmural myocardial infarctionchronic heart failureexperimental therapy terms of 15 days and 28 daysprevention and therapy

Identifiers

PMID33893957
OpenAlexW3110839891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.